News room
Celebrating 20 Years of Technophage
Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating...
TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections
TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative...
Fostering Collaboration: Technophage Joins REVERSE 2 Investigator Meeting in Hyderabad to Advance TP-102 Development
We are delighted to share that Technophage’s Clinical Trial Director, Margarida Barreto, participated in the REVERSE 2 / TP-102_102 Investigator...
Technophage is looking for a Phage Scientist to join the team
Technophage is currently seeking a Phage Scientist to join our Research team. The ideal candidate will hold an MSc or PhD in Biology, Biochemistry,...
TP-102 Phase I/IIa clinical trial results published in Med by Cell Press
Technophage is excited to kick off the new year by sharing our latest publication in Med by Cell Press. Our Phase I/IIa study results for TP-102, an...